title: Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment (the LIFE study).
abstract: OBJECTIVE
  We tested the impact of isolated systolic hypertension (ISH) on normalization of left ventricular (LV) structure during antihypertensive treatment.
  
  
  METHODS
  Baseline and annual echocardiograms were recorded in 873 hypertensive patients with electrocardiographic signs of LV hypertrophy during 4.8 years randomized losartan- or atenolol-based antihypertensive treatment in the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study and classified as having ISH (n = 128) if systolic BP ≥ 160 mmHg and diastolic BP < 90 mmHg, or non-ISH divided into two groups by systolic BP ≥ 160 mmHg (non-ISH ≥ 160 mmHg) (n = 645) and systolic BP < 160 mm Hg (n = 100) (non-ISH < 160 mmHg), respectively.
  
  
  RESULTS
  Patients with ISH were older, with higher prevalence of diabetes than non-ISH groups and higher pulse pressure/stroke volume index (all p < 0.05). Baseline systolic blood pressure (BP) differed between groups and was highest in the non-ISH ≥ 160 mmHg group (p < 0.05). Systolic BP reduction was less in the ISH group (p < 0.05). LV geometry did not differ between ISH and non-ISH ≥ 160 mmHg groups at baseline, but ISH had more residual LV hypertrophy of concentric type at the last study visit (p < 0.05). In multivariate analysis, less reduction of LV mass was predicted by ISH (β = - 0.07) independent of significant associations with baseline LVMi (β = 0.52) and atenolol-based treatment (β = - 0.08) and clinical confounders (all p < 0.05).
  
  
  CONCLUSIONS
  ISH is associated with impaired normalization of LV mass during systematic antihypertensive treatment. The findings may help explain the higher cardiovascular event rate previously reported in ISH patients.
authors.affiliation: Department of Clinical Science, University of Bergen , Bergen , Norway.
authors.forename: Costantino
authors.initials: C
authors.lastname: Mancusi
authors.forename: Eva
authors.initials: E
authors.lastname: Gerdts
authors.forename: Giovanni
authors.initials: G
authors.lastname: De Simone
authors.forename: Yassein M
authors.initials: YM
authors.lastname: Abdelhai
authors.forename: Mai Tone
authors.initials: MT
authors.lastname: Lønnebakken
authors.forename: Kurt
authors.initials: K
authors.lastname: Boman
authors.forename: Kristian
authors.initials: K
authors.lastname: Wachtell
authors.forename: Björn
authors.initials: B
authors.lastname: Dahlöf
authors.forename: Richard B
authors.initials: RB
authors.lastname: Devereux
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001262:Atenolol / Q000008:administration & dosage; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D017379:Hypertrophy, Left Ventricular / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*; D019808:Losartan / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D013599:Systole
chemical_list: D000959:Antihypertensive Agents; D001262:Atenolol; D019808:Losartan
keywords: Arterial stiffness; isolated systolic hypertension; left ventricular hypertrophy